Resumo

TORRES MCCOOK, Angel Ramón; RODRIGUEZ TANTY, Chryslaine  e  GARCIA PUPO, Laura. CHOLINESTERASE ACTIVITY INHIBITORS AS SYMPTOMATIC THERAPY FOR ALZHEIMER’S DISEASE. Rev. CENIC Cienc. Biol [online]. 2023, vol.54, pp. 44-68.  Epub 15-Set-2023. ISSN 2221-2450.

Alzheimer's disease is one of the leading causes of dementia today. This neurodegenerative disorder results in the progressive decline of cognitive ability and memory. The biochemical processes that characterize this disease include the formation of β-amyloid plaques, the development of neurofibrillary tangles, and the loss of cholinergic neurons in the cerebral cortex. In fact, most of the drugs available to deal with this disease are directed at the affectations suffered by diseased individuals in the cholinergic synapse of the Central Nervous System. It is for this reason that the development of drugs directed to therapeutic targets that allow increasing the availability of acetylcholine in the cholinergic synapse is a field of research of great interest. However, success in the clinical use of these compounds is limited by the side effects they produce and by the multifactorial nature of this disease. The present review aims to provide an overview of the cholinergic dysfunction observed in Alzheimer's disease patients that supports the cholinergic hypothesis in its pathophysiology. In addition, cholinesterase activity inhibitors of clinical and innovative use are discussed as an alternative symptomatic therapy for Alzheimer's disease.

Palavras-chave : inhibition; acetylcholinesterase; Cholinergic Hypothesis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )